Otelixizumab
As of the edition of 20 October 2026, Otelixizumab is an antibody: went quiet in 2018; acts on CD3E.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Antibody
- Registered trials
- 7, 3 stopped early
- Disease areas
- Hormones; Immune system; Nutrition and metabolism; Eye; Infections; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Otelixizumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD3E | T-cell surface glycoprotein CD3 epsilon chain | P07766 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 1 | 0 | 3 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2006 to now |